Best Hospitals for Patent Ductus Arteriosus (PDA) Device Closure in Chennai, India

The ductus arteriosus is a physiologically essential fetal vascular channel that connects the main pulmonary artery to the descending thoracic aorta, allowing oxygenated placental blood to bypass the fluid-filled, non-functioning fetal lungs. In healthy full-term neonates, this vessel constricts and functionally closes within 12–72 hours of birth, driven by rising arterial oxygen tension, declining prostaglandin E2 levels, and smooth muscle contraction. When this closure fails — a condition termed Patent Ductus Arteriosus — a persistent left-to-right shunt develops, diverting oxygenated blood from the systemic circulation back into the pulmonary circuit. The hemodynamic burden is proportional to the diameter and length of the PDA: large, non-restrictive ducts impose significant volume overload on the left atrium and left ventricle, predisposing to left ventricular dilation, pulmonary arterial hypertension (PAH), recurrent lower respiratory tract infections, failure to thrive in infants, and, if uncorrected over years, Eisenmenger syndrome — an irreversible pulmonary vascular obstructive disease that renders closure contraindicated.

• ELIGIBLE PATIENTS — HEMODYNAMIC CRITERIA:
• Symptomatic PDA of any age with pulmonary-to-systemic flow ratio (Qp:Qs) ≥ 1.5:1 confirmed on cardiac catheterization or Doppler echocardiography
• Asymptomatic moderate-to-large PDA with evidence of left ventricular volume overload (left atrial enlargement, LV end-diastolic dimension z-score > +2 on echo)
• Small 'silent' PDA in adults with a history of infective endocarditis or at high endocarditis risk (professional guidelines vary; most centers close these)
• Body weight ≥ 6 kg for standard Amplatzer Duct Occluder (ADO-I) deployment; newer ADO-II and Occlutech Duct Occluder devices extend candidacy to infants 3–5 kg
• +19 more

PHARMACOLOGICAL CLOSURE (Neonates and Premature Infants Only):

Indomethacin (COX non-selective inhibitor, 0.1–0.25 mg/kg IV every 12–24 hours × 3 doses) or ibuprofen lysine (10 mg/kg then 5 mg/kg × 2 doses) reduce prostaglandin E2-mediated ductal patency, achieving closure in 70–80% of preterm infants when administered within the first 1–2 weeks of life. Oral/IV acetaminophen (paracetamol) is an emerging, better-tolerated alternative with comparable efficacy data in recent randomized trials. Pharmacological therapy is not effective in term neonates or older patients due to mature ductal histology (fibromuscular transformation). Failure or contraindication to pharmacological closure (renal impairment, thrombocytopenia, active necrotizing enterocolitis, intracranial hemorrhage) mandates transcatheter or surgical intervention.

TRANSCATHETER DEVICE CLOSURE (Preferred Standard of Care — All Age Groups ≥ 3 kg in Suitable Anatomy):

Performed in a cardiac catheterization laboratory under general anesthesia (infants/children) or conscious sedation (adolescents/adults), with continuous fluoroscopic guidance and real-time intracardiac or transesophageal echocardiographic monitoring.

PHASE 1 — PRE-ARRIVAL CONSULTATION (2–4 weeks before travel):

• Patient family submits echocardiography reports, catheterization data (if prior), growth charts, and medical records to GAF Healthcare's medical coordination team
• Remote case review by the destination center's pediatric cardiologist and interventional cardiologist; written opinion issued within 48–72 hours
• GAF Healthcare coordinates e-Medical Visa application (India) or entry visa facilitation (UAE) in parallel
• Pre-procedure blood tests, CBC, coagulation, renal panel, blood group arranged at local facility using a standardized requisition form issued by the destination center
• Dental clearance and ENT review for active infection recommended 2 weeks prior
• Anesthesia pre-assessment questionnaire completed remotely for infants under general anesthesia

PHASE 2 — ARRIVAL AND PRE-PROCEDURE WORKUP (Days 1–2 in destination):